​

Kyntra Bio Stock (NASDAQ:KYNB)

ForecastRevenueFinancialsChartTranscripts
Kyntra Bio by TradingView

Previous Close

$6.97

52W Range

$4.85 - $12.60

50D Avg

$8.40

200D Avg

$8.93

Market Cap

$28.03M

Avg Vol (3M)

$35.29K

Beta

0.83

Div Yield

-

KYNB Company Profile

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

225

IPO Date

Nov 14, 2014

Website

KYNB Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Drug Product Revenue$27.67M$18.75M$11.09M

Fiscal year ends in Dec 24 | Currency in USD

KYNB Financial Summary

Dec 24Dec 23Dec 22
Revenue$29.62M$46.80M$140.73M
Operating Income$-150.42M$-322.72M$-301.02M
Net Income$-47.58M$-284.23M$-293.65M
EBITDA$-142.43M$-305.20M$-282.82M
Basic EPS$-0.48$-2.92$-3.15
Diluted EPS$-0.48$-2.92$-3.15

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 10, 25 | 5:00 PM
Q2 25Aug 11, 25 | 5:00 PM
Q1 25May 12, 25 | 5:00 PM

Peer Comparison

TickerCompany
MRSNMersana Therapeutics, Inc.
KZRKezar Life Sciences, Inc.
OKUROnKure Therapeutics, Inc.
CELUCelularity Inc.
TPSTTempest Therapeutics, Inc.
XLOXilio Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
XFORX4 Pharmaceuticals, Inc.
ALGSAligos Therapeutics, Inc.